SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, BCMA, CAR-T, CD19, Dual/triple agonist

October 31, 2023

An ARI-0003 Trial to Be Initiated by Hospital Clinic; Mustang’s MB-109 Receives IND Clearance from the FDA

Here is a brief preview of this blast: On Tuesday, October 24, a new early Ph1 CARTD-BG-1 trial evaluating ARI-0003 (BCMA x CD19 CAR-T), an academic CAR-T developed by the Hospital Clinic of Barcelona, Spain, in r/r B-cell aggressive lymphoma was posted on CT.gov. Moreover, on Thursday, October 26, Mustang Bio announced FDA acceptance of the IND application to evaluate MB-109 [MB‐101 (IL13Rα2 CAR-T) + MB-108 (HSV1 oncolytic virus)] in recurrent glioblastoma (GBM) and high-grade astrocytoma (press release). Below, Celltelligence provides insights on both cell therapies, discussing their potential advantages.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.